Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orquest plans launch in 2000 for Healos:

This article was originally published in Clinica

Executive Summary

Orquest, a Mountain View, California-based orthobiologics company, plans to launch its Healos bone graft substitute for spinal fusion in Europe next year. The company has a strategic alliance with Sulzer Spine-Tech for the CE-marked product, which is being evaluated for use with the BAK line of interbody fusion cages. The company is also developing an integrated growth differentiation factor-5, Healos/GDF-5, as a replacement for autograft. Another product, Ossigel, is designed to accelerate fracture healing by stimulating cell division and blood vessel formation within the fracture site. Ossigel, which is an injectable formulation of basic fibroblast growth factor and hyaluronic acid gel, is currently in clinical trials in the US and Europe.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT079374

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel